

International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

AI and Precision Medicine in Breast Cancer: Towards Truly Personalized Care

Somashekhar SP¹

¹Department of Surgical Oncology, Aster International Institute of Oncology, Aster Hospital, Aster CMI Hospital, No. 43/2, New Airport Road, NH44, Sahakar Nagar, Hebbal, Bangalore 560092, India drspsomashekhar@gmail.com

ABSTRACT

Background:

Breast cancer remains the most frequently diagnosed malignancy and one of the leading causes of cancer-related mortality among women worldwide despite remarkable advances in screening, molecular diagnostics, targeted therapies, and personalized treatment strategies. The extraordinary biological heterogeneity of breast cancer, characterized by diverse molecular subtypes, genomic alterations, tumor microenvironment interactions, hormonal influences, and immune responses, presents significant challenges to conventional population-based treatment approaches. Recent developments in artificial intelligence (AI), computational oncology, multimodal data integration, and precision medicine have transformed breast cancer management by enabling individualized diagnosis, prognostic prediction, therapeutic optimization, recurrence monitoring, and survivorship care. Artificial intelligence integrates mammography, digital breast tomosynthesis, magnetic resonance imaging, ultrasound, digital pathology, genomic sequencing, transcriptomics, proteomics, laboratory biomarkers, electronic health records, and longitudinal clinical information into comprehensive computational models capable of supporting personalized clinical decision-making. Advances in machine learning, deep learning, transformer architectures, foundation models, graph neural networks, reinforcement learning, and explainable artificial intelligence have significantly enhanced breast cancer detection, molecular classification, treatment selection, prediction of therapeutic response, toxicity assessment, and long-term disease surveillance. Despite remarkable progress, important challenges remain regarding data interoperability, computational scalability, ethical governance, cybersecurity, regulatory validation, and equitable clinical implementation. This review provides a comprehensive overview of artificial intelligence-driven precision medicine in breast cancer, highlighting computational foundations, current clinical applications, emerging innovations, and future perspectives toward truly personalized breast cancer care.[1]

Keywords: Breast cancer, Artificial intelligence, Precision medicine, Mammography, Digital pathology, Radiomics, Personalized medicine, Machine learning, Oncology imaging, Clinical decision support.

Article Info

Received: 05 May 2026, received in revised form: 15 May 2026, accepted: 20 May 2026, available online: 30 May 2026; Volume: 2; Issue: 5; Pages: 01-10.

Citation: Somashekhar SP., 2026. AI and Precision Medicine in Breast Cancer: Towards Truly Personalized Care. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)* 2(5): 01-10.

DOI:

Introduction

Breast cancer is the most commonly diagnosed cancer among women worldwide and remains one of the leading causes of cancer-related mortality despite substantial advances in prevention, screening, diagnosis, and treatment. Improvements in mammographic screening, molecular diagnostics, targeted therapies, endocrine therapy, immunotherapy, and multidisciplinary clinical management have significantly enhanced patient survival. Nevertheless, considerable variability in treatment response, disease recurrence, and long-term outcomes continues to challenge modern breast oncology.[2]

Breast cancer is a biologically heterogeneous disease comprising multiple molecular subtypes including luminal A, luminal B, HER2-positive, and triple-negative breast cancer. These subtypes differ substantially in genomic alterations, hormone receptor expression, immune microenvironment, metastatic behavior, therapeutic sensitivity, and prognosis. Consequently, patients with similar histopathological diagnoses frequently exhibit markedly different clinical outcomes, highlighting the limitations of traditional population-based treatment strategies.[3]

Modern breast oncology increasingly relies upon large quantities of heterogeneous biomedical information generated through mammography, digital breast tomosynthesis, breast magnetic resonance imaging, ultrasound, digital pathology, genomic sequencing, transcriptomics, proteomics, laboratory investigations, wearable

technologies, and electronic health records. Integrating these diverse datasets into individualized treatment decisions represents one of the greatest challenges in contemporary precision medicine.[4]

Artificial intelligence has emerged as one of the most transformative technologies supporting breast cancer management by enabling automated interpretation of imaging, pathology, molecular biology, and clinical information. Deep learning algorithms identify tumors with remarkable accuracy, machine learning predicts therapeutic response, transformer architectures analyze clinical documentation, and multimodal artificial intelligence integrates diverse biomedical information into unified patient-specific computational models.[5]

Artificial intelligence-driven precision medicine now supports personalized diagnosis, molecular classification, individualized treatment planning, recurrence prediction, toxicity assessment, and long-term survivorship management, representing a major paradigm shift toward truly personalized breast cancer care.[6]

2. Evolution of Precision Medicine in Breast Cancer

The management of breast cancer has evolved dramatically from conventional histopathological classification toward comprehensive molecular characterization and personalized treatment. Historically, therapeutic decisions were based primarily on tumor size, lymph node involvement, histological grade, and clinical stage. Although these approaches substantially improved patient outcomes, they frequently failed to capture the underlying biological diversity of breast cancer.[7]

Advances in molecular biology transformed understanding of breast cancer through identification of hormone receptor status, HER2 amplification, BRCA1 and BRCA2 mutations, PIK3CA alterations, TP53 mutations, immune biomarkers, and gene expression signatures. High-throughput genomic technologies further enabled comprehensive molecular profiling, leading to development of individualized therapeutic strategies based on tumor biology rather than anatomical characteristics alone.[8]

Artificial intelligence accelerated this transition by integrating imaging, pathology, genomics, laboratory investigations, and clinical information into predictive computational models capable of supporting highly individualized clinical decision-making. Machine learning algorithms identify complex biological relationships that remain difficult to detect using conventional statistical approaches while improving diagnosis, prognostic prediction, and treatment selection.[9]

Recent developments in multimodal learning, transformer architectures, foundation models, and computational oncology have further expanded precision breast cancer care by enabling continuous integration of newly acquired patient information throughout diagnosis, treatment, and survivorship.[10]

Today, artificial intelligence represents one of the central computational foundations of precision medicine in breast cancer by supporting adaptive, patient-specific healthcare throughout the entire cancer care continuum.[11]

3. Computational Foundations of Artificial Intelligence in Breast Oncology

Artificial intelligence-driven precision medicine relies on multiple complementary computational methodologies capable of analyzing heterogeneous biomedical information across molecular, anatomical, physiological, and clinical domains. Rather than functioning as isolated predictive algorithms, modern breast oncology integrates several artificial intelligence approaches operating simultaneously to generate individualized clinical insights.[12]

Traditional machine learning algorithms—including logistic regression, support vector machines, decision trees, random forests, and gradient boosting models—initially demonstrated considerable success in predicting recurrence, therapeutic response, metastasis, and survival using structured clinical datasets. Although highly effective, these approaches generally depended upon manually engineered features and limited biological representation.[13]

Deep learning significantly expanded computational capabilities by automatically extracting hierarchical features from mammography, breast magnetic resonance imaging, ultrasound, digital pathology, genomic information, and longitudinal clinical records. Convolutional neural networks revolutionized image interpretation, whereas recurrent neural networks facilitated temporal analysis of treatment response and disease progression.[14]

Transformer architectures have recently become central to breast precision oncology because self-attention mechanisms efficiently integrate imaging findings, pathology reports, genomic sequencing, laboratory biomarkers, medication history, physician documentation, and electronic health records into unified patient representations supporting individualized therapeutic recommendations.[15]

Foundation models pretrained on enormous biomedical datasets further enhance scalability through transfer learning, allowing adaptation across multiple breast cancer subtypes while improving robustness, generalizability, and computational efficiency.[16]

4. Multimodal Data Integration for Precision Breast Cancer Care

The effectiveness of precision medicine depends fundamentally upon integration of heterogeneous biomedical information into comprehensive computational frameworks. Breast cancer develops through complex interactions among genomic mutations, hormonal regulation, immune responses, angiogenesis, metabolism, environmental

exposures, and therapeutic interventions. Consequently, no single data source adequately captures the complete biological complexity of individual tumors.[17]

Breast imaging contributes detailed anatomical and functional information regarding tumor morphology, vascularity, tissue density, multifocal disease, nodal involvement, and treatment response. Digital pathology provides microscopic evaluation of tumor architecture, histological grade, immune infiltration, stromal remodeling, angiogenesis, and cellular differentiation. Molecular profiling identifies clinically actionable genomic alterations, transcriptomic signatures, proteomic pathways, and epigenetic modifications associated with prognosis and therapeutic response.[18]

Clinical information—including laboratory investigations, hormonal status, reproductive history, medication exposure, family history, lifestyle characteristics, treatment records, and longitudinal follow-up—adds essential context supporting individualized patient management. Artificial intelligence harmonizes these heterogeneous datasets through multimodal representation learning capable of identifying hidden biological relationships beyond conventional statistical analysis.[19]

Continuous integration of newly acquired patient information enables adaptive precision medicine throughout diagnosis, treatment, recurrence, and survivorship while supporting highly personalized healthcare.[20]

5. Artificial Intelligence in Breast Cancer Screening

Early detection remains one of the most effective strategies for reducing breast cancer mortality. Artificial intelligence has substantially improved breast cancer screening by increasing diagnostic accuracy, reducing false-positive examinations, minimizing unnecessary biopsies, and assisting radiologists in identifying subtle abnormalities that may otherwise remain undetected.

Deep learning algorithms demonstrate exceptional performance in mammography, digital breast tomosynthesis, ultrasound, magnetic resonance imaging, and contrast-enhanced mammography through automated identification of masses, calcifications, architectural distortion, asymmetries, and suspicious lesions. These computational systems improve cancer detection while reducing interobserver variability and interpretation workload.[21]

Artificial intelligence further enables individualized screening strategies by integrating imaging findings with family history, genomic susceptibility, breast density, hormonal factors, reproductive history, and clinical risk profiles. Personalized screening recommendations improve early diagnosis while reducing unnecessary investigations among lower-risk individuals.[22]

6. Artificial Intelligence in Breast Imaging

Medical imaging remains one of the central pillars of precision breast oncology because imaging provides essential information throughout diagnosis, staging, treatment planning, therapeutic monitoring, and long-term surveillance. Mammography, digital breast tomosynthesis, magnetic resonance imaging, ultrasound, positron emission tomography, and hybrid imaging collectively generate extensive diagnostic information regarding tumor biology.

Deep learning algorithms automatically detect breast lesions, segment tumors, quantify lesion volume, characterize imaging phenotypes, estimate nodal involvement, and evaluate treatment response with remarkable precision. Automated image interpretation substantially enhances radiologist performance while supporting evidence-based multidisciplinary decision-making.[23]

Radiomics further expands the clinical value of breast imaging by extracting quantitative imaging biomarkers describing tumor heterogeneity, vascularity, morphology, texture, metabolism, and spatial organization. Integration of imaging biomarkers with molecular and clinical information substantially improves individualized prognostic prediction and treatment planning.[24]

7. Artificial Intelligence in Digital Pathology and Molecular Classification

Digital pathology has become an indispensable component of precision breast oncology. Whole-slide imaging enables digitization of breast tissue specimens at ultra-high resolution, allowing deep learning algorithms to evaluate millions of microscopic image regions simultaneously while maintaining exceptional diagnostic accuracy.

Transformer-based computational pathology models automatically identify histomorphological features associated with tumor subtype, histological grade, lymphovascular invasion, immune infiltration, stromal remodeling, angiogenesis, necrosis, mitotic activity, and metastatic potential. These microscopic biomarkers significantly improve diagnosis, prognostic prediction, and individualized treatment planning.[25]

Artificial intelligence also enables prediction of clinically relevant molecular biomarkers directly from histopathological images. Deep learning algorithms have demonstrated the capability to infer estrogen receptor status, progesterone receptor status, HER2 amplification, BRCA-associated signatures, PIK3CA mutations, TP53 alterations, Ki-67 proliferation index, PD-L1 expression, and molecular subtypes from routine tissue morphology. These computational approaches may reduce dependence on expensive molecular testing while accelerating precision oncology workflows.[26]

Integration of digital pathology with imaging, genomics, laboratory biomarkers, and clinical information substantially enhances molecular classification, therapeutic selection, and long-term outcome prediction across all major breast cancer subtypes.[27]

8. Radiomics and Radiogenomics in Breast Cancer

Radiomics has emerged as one of the most significant innovations in breast cancer imaging by extracting hundreds of quantitative imaging biomarkers from mammography, digital breast tomosynthesis, magnetic resonance imaging, ultrasound, and positron emission tomography. Unlike conventional qualitative interpretation, radiomics objectively characterizes tumor morphology, texture, vascularity, heterogeneity, metabolism, and spatial organization using advanced computational analysis.[28]

Radiogenomics further integrates these imaging biomarkers with genomic sequencing, transcriptomics, proteomics, and molecular diagnostics to identify imaging phenotypes associated with underlying tumor biology. Artificial intelligence establishes complex relationships between radiological features and clinically significant molecular alterations including BRCA1/2 mutations, HER2 amplification, PIK3CA mutations, TP53 alterations, estrogen receptor status, progesterone receptor status, and molecular subtype classification.[29]

Integration of radiogenomics into precision medicine enables continuous, non-invasive monitoring of tumor evolution throughout treatment. Serial imaging examinations provide updated molecular insights without repeated tissue biopsies, allowing clinicians to evaluate therapeutic response, disease progression, and emerging resistance mechanisms more effectively.[30]

9. Artificial Intelligence in Personalized Therapeutic Planning

Personalized treatment planning represents one of the greatest clinical advantages of artificial intelligence in breast oncology. Rather than relying exclusively on standardized treatment protocols, AI enables clinicians to evaluate multiple therapeutic strategies according to each patient's tumor biology, imaging characteristics, molecular profile, and clinical condition.

Machine learning algorithms estimate chemotherapy sensitivity, endocrine therapy response, HER2-targeted therapy efficacy, immunotherapy benefit, radiation sensitivity, recurrence probability, progression-free survival, and overall survival using multimodal biomedical information. These predictive models allow physicians to compare therapeutic strategies while minimizing unnecessary toxicity and maximizing clinical benefit.[31]

Artificial intelligence continuously updates treatment recommendations by incorporating serial imaging findings, laboratory biomarkers, pathology reports, genomic alterations, and therapeutic response throughout the patient's cancer journey. This adaptive approach supports dynamic precision medicine rather than static treatment planning.[32]

10. Artificial Intelligence in Immunotherapy and Targeted Therapy

The development of targeted therapies and immunotherapy has fundamentally changed breast cancer treatment, particularly for HER2-positive and triple-negative breast cancer. However, only selected patients derive durable benefit, making prediction of therapeutic response an important objective of precision oncology.

Artificial intelligence integrates genomic alterations, tumor mutational burden, PD-L1 expression, immune-cell composition, tumor-infiltrating lymphocytes, radiological imaging, digital pathology, laboratory biomarkers, and clinical characteristics into predictive computational models estimating individualized response to immunotherapy and targeted treatment.[33]

Machine learning algorithms further assist clinicians in optimizing immune checkpoint inhibitors, antibody-drug conjugates, HER2-targeted therapies, PARP inhibitors, CDK4/6 inhibitors, PI3K inhibitors, endocrine therapies, and combination treatment strategies while minimizing treatment-related adverse effects.[34]

11. Artificial Intelligence in Neoadjuvant and Adjuvant Therapy

Neoadjuvant and adjuvant therapies play central roles in modern breast cancer management by reducing recurrence risk and improving long-term survival. Artificial intelligence significantly enhances therapeutic decision-making through prediction of pathological complete response, residual disease, treatment resistance, and postoperative recurrence.

Deep learning algorithms analyze imaging, pathology, genomic sequencing, circulating biomarkers, and treatment response to estimate the likelihood of achieving complete pathological response before surgery. These predictive insights support individualized treatment intensification or de-escalation according to each patient's biological characteristics.[35]

Artificial intelligence also assists postoperative management by estimating recurrence probability, distant metastasis risk, treatment-related toxicity, and long-term survival while recommending personalized follow-up schedules and surveillance strategies.[36]

12. Artificial Intelligence in Drug Discovery and Clinical Trials

Artificial intelligence has substantially accelerated breast cancer drug discovery by integrating systems biology, pharmacology, molecular chemistry, genomics, and computational oncology into predictive research platforms capable of identifying novel therapeutic opportunities.

Machine learning algorithms identify molecular targets, simulate drug-target interactions, estimate pharmacokinetic and pharmacodynamic properties, optimize dosing strategies, and predict therapeutic toxicity before laboratory or clinical evaluation. These computational simulations reduce research costs while improving candidate selection for clinical development.[37]

Artificial intelligence also improves clinical trial design through individualized patient stratification, prediction of therapeutic response, optimization of eligibility criteria, reduction of trial variability, and support for adaptive clinical trial methodologies. Imaging-derived biomarkers and molecular signatures further facilitate development of objective surrogate endpoints for therapeutic evaluation.[38]

13. Explainable Artificial Intelligence and Trustworthy Precision Medicine

Clinical implementation of artificial intelligence requires transparent computational models capable of explaining diagnostic and therapeutic recommendations. Explainable artificial intelligence (XAI) addresses this requirement by providing interpretable visual and quantitative explanations rather than functioning as opaque "black-box" systems.

Saliency maps identify mammographic, magnetic resonance imaging, ultrasound, or pathological image regions contributing most strongly to diagnostic predictions, enabling clinicians to verify biologically relevant imaging features. SHAP (Shapley Additive Explanations) values estimate the contribution of imaging biomarkers, laboratory investigations, genomic alterations, molecular characteristics, and clinical variables to individualized predictions, while counterfactual explanations illustrate how changes in patient characteristics influence predicted outcomes.[39]

Explainable artificial intelligence improves physician confidence, facilitates multidisciplinary communication, reduces algorithmic bias, supports regulatory approval, and promotes responsible implementation of artificial intelligence across breast oncology practice.[40]

14. Federated Learning, Cybersecurity, and Ethical Considerations

Large-scale precision breast oncology requires collaboration among cancer centers, breast imaging facilities, pathology laboratories, genomic sequencing centers, and international research networks. However, direct sharing of sensitive patient information raises important concerns regarding privacy, confidentiality, cybersecurity, and ethical governance.

Federated learning enables collaborative artificial intelligence development without transferring raw patient data between participating institutions. Individual hospitals train algorithms locally using their own imaging, pathology, genomic, and clinical datasets, while only encrypted model parameters are securely aggregated into improved global models. This decentralized learning strategy preserves patient privacy while enabling continuous learning from geographically diverse patient populations.[41]

Additional privacy-preserving technologies—including differential privacy, homomorphic encryption, secure multi-party computation, blockchain-based audit systems, and encrypted cloud computing—further strengthen cybersecurity within precision breast cancer ecosystems. Robust authentication protocols, secure communication channels, identity management systems, intrusion detection technologies, and continuous cybersecurity monitoring remain essential because artificial intelligence platforms continuously exchange highly sensitive biomedical information across interconnected healthcare infrastructures.[42]

15. Digital Biomarkers and Continuous Patient Monitoring

The rapid expansion of wearable technologies, mobile health applications, biosensors, and remote physiological monitoring has significantly enhanced precision breast cancer care. Unlike conventional follow-up strategies based primarily on scheduled clinical visits, digital health technologies enable continuous assessment of patient physiology, treatment tolerance, physical activity, sleep quality, cardiovascular function, and quality of life throughout diagnosis, treatment, and survivorship. These continuously generated physiological measurements serve as digital biomarkers capable of reflecting dynamic changes in patient health status.[43]

Artificial intelligence continuously integrates physiological measurements with imaging findings, laboratory biomarkers, treatment history, medication adherence, electronic health records, and patient-reported outcomes to identify early signs of treatment-related toxicity, disease recurrence, postoperative complications, and functional decline. Early recognition of these changes enables timely clinical intervention while improving long-term outcomes.

Continuous monitoring further supports personalized survivorship by allowing clinicians to adapt follow-up schedules according to individualized recurrence risk rather than standardized surveillance protocols. Integration of wearable technologies with intelligent clinical decision-support systems therefore extends precision oncology beyond traditional hospital settings while improving patient engagement and quality of life.[44]

16. Artificial Intelligence in Survivorship and Long-Term Care

Advances in breast cancer diagnosis and treatment have substantially increased the number of long-term survivors worldwide. Consequently, survivorship care has become an increasingly important component of precision oncology. Many survivors experience chronic complications including cardiovascular disease, osteoporosis, endocrine dysfunction, lymphedema, cognitive impairment, fatigue, infertility, premature menopause, psychosocial distress, and secondary malignancies.

Artificial intelligence supports individualized survivorship by integrating treatment history, genomic susceptibility, hormonal status, imaging findings, laboratory investigations, lifestyle factors, wearable technologies, and longitudinal clinical information into predictive computational models. Machine learning algorithms estimate individualized risks of recurrence, late treatment-related toxicity, cardiovascular complications, endocrine disorders, and secondary cancers while recommending personalized surveillance schedules and preventive interventions.[45] These individualized survivorship strategies improve quality of life while reducing unnecessary investigations, supporting evidence-based long-term healthcare for breast cancer survivors.

17. Emerging Innovations in Artificial Intelligence

Rapid advances in computational medicine continue to expand the capabilities of artificial intelligence in breast oncology. Foundation models trained on enormous multimodal biomedical datasets are expected to improve diagnostic performance across imaging, pathology, genomics, and clinical decision support while requiring substantially less task-specific retraining.

Generative artificial intelligence has demonstrated considerable potential for biomarker discovery, therapeutic target identification, molecular design, synthetic biomedical data generation, automated clinical documentation, image reconstruction, educational simulation, and scientific hypothesis generation. Reinforcement learning algorithms further optimize adaptive treatment strategies by continuously learning from patient outcomes and refining therapeutic recommendations throughout disease progression.[46]

Graph neural networks increasingly model complex biological interactions among genes, proteins, immune pathways, tumor microenvironment, metabolic networks, and signaling cascades, providing deeper understanding of breast cancer biology while facilitating identification of novel therapeutic opportunities and individualized treatment strategies.[47]

18. Integrated Artificial Intelligence Ecosystems in Breast Oncology

Future breast cancer care will increasingly operate within intelligent healthcare ecosystems integrating breast imaging, pathology, genomics, molecular diagnostics, surgery, radiation oncology, medical oncology, pharmacy, rehabilitation, telemedicine, wearable technologies, and electronic health records into unified computational platforms.

Artificial intelligence serves as the computational foundation connecting these diverse healthcare components through continuous multimodal learning and real-time clinical decision support. Such integrated ecosystems facilitate seamless communication among radiologists, pathologists, surgeons, medical oncologists, radiation oncologists, genetic counselors, pharmacists, rehabilitation specialists, and primary care physicians while improving treatment coordination, medication safety, survivorship care, and patient-centered management.[48]

Cloud computing, edge computing, blockchain technology, Internet of Medical Things (IoMT), secure interoperability standards, and high-performance computational infrastructure are expected to further improve scalability, accessibility, computational efficiency, and secure information exchange across future breast oncology networks.[49]

19. Future Perspectives

The future of precision breast oncology is increasingly centered on intelligent computational systems capable of continuously integrating imaging, pathology, genomics, transcriptomics, proteomics, laboratory investigations, wearable technologies, physiological monitoring, and longitudinal clinical information into adaptive patient-specific healthcare models.

Future research should prioritize large multicenter prospective studies evaluating real-world implementation of artificial intelligence across diverse healthcare systems and patient populations. Standardization of imaging acquisition, molecular diagnostics, pathology workflows, validation methodologies, interoperability frameworks, explainability standards, and regulatory pathways will be essential for widespread clinical implementation.[50]

International collaboration among radiologists, breast surgeons, oncologists, pathologists, biomedical engineers, molecular biologists, computer scientists, regulatory agencies, and healthcare organizations will accelerate development of trustworthy, scalable, and equitable artificial intelligence platforms capable of supporting routine breast cancer care worldwide.[51]

20. Discussion

Artificial intelligence has become one of the most transformative technologies in precision breast oncology by enabling comprehensive integration of imaging, pathology, genomics, molecular diagnostics, laboratory investigations, wearable technologies, and longitudinal clinical information into unified computational frameworks.

Applications including breast cancer screening, diagnostic imaging, molecular classification, radiogenomics, therapeutic optimization, immunotherapy prediction, recurrence monitoring, survivorship care, and multidisciplinary clinical decision support demonstrate the broad clinical utility of artificial intelligence. Rather than replacing clinicians, intelligent computational systems function as evidence-based partners that enhance diagnostic accuracy, workflow efficiency, treatment selection, and patient-centered care while preserving physician expertise.[52]

Despite remarkable advances, important challenges remain before routine implementation becomes feasible. Data heterogeneity, interoperability limitations, algorithmic bias, computational complexity, cybersecurity concerns, ethical governance, regulatory approval, healthcare disparities, and clinician acceptance continue to represent major barriers. Addressing these challenges will require transparent governance, multidisciplinary collaboration, prospective validation, and internationally harmonized standards to ensure safe, equitable, and responsible implementation of artificial intelligence within breast oncology.[53]

21. Conclusion

Artificial intelligence is redefining precision medicine in breast cancer by enabling comprehensive integration of multimodal biomedical information into individualized clinical decision-making. Through advanced analysis of mammography, magnetic resonance imaging, ultrasound, digital pathology, genomics, laboratory biomarkers, wearable technologies, electronic health records, and patient-reported outcomes, artificial intelligence supports personalized diagnosis, molecular characterization, therapeutic optimization, recurrence prediction, toxicity assessment, and survivorship care.[54]

Continued advances in foundation models, explainable artificial intelligence, federated learning, multimodal learning, graph neural networks, reinforcement learning, and generative artificial intelligence are expected to further improve diagnostic accuracy, computational efficiency, scalability, interpretability, and accessibility across breast oncology.[55]

Although important scientific, technical, ethical, and regulatory challenges remain, ongoing interdisciplinary research continues to accelerate translation of artificial intelligence into routine clinical practice. By supporting predictive analytics, adaptive monitoring, individualized treatment planning, and lifelong survivorship management, artificial intelligence has the potential to improve survival, reduce treatment-related complications, enhance quality of life, and establish the foundation for the next generation of personalized breast cancer care worldwide.[56]

Future integration of artificial intelligence with digital biomarkers, computational modeling, precision therapeutics, multimodal learning, and collaborative international research networks is expected to transform breast oncology into a continuously learning healthcare ecosystem capable of delivering safer, more effective, and truly individualized care for every patient diagnosed with breast cancer.[57]

As advances in computational medicine continue to evolve, artificial intelligence will play an increasingly central role in reducing healthcare disparities, accelerating therapeutic discoveries, improving clinical workflows, optimizing survivorship outcomes, and advancing the global vision of truly personalized breast cancer care based on each patient's unique biological characteristics and clinical needs.[58]

Continued investment in interdisciplinary collaboration, prospective validation studies, secure digital infrastructure, and ethical implementation will ensure that artificial intelligence remains a trusted and effective partner in modern breast oncology. Such efforts will support integration of precision medicine into routine healthcare while maintaining patient safety, transparency, and clinical excellence.[59]

Ultimately, the convergence of artificial intelligence, multimodal precision medicine, molecular oncology, advanced imaging, and personalized therapeutics is expected to redefine breast cancer management, enabling earlier diagnosis, more accurate prognostic prediction, optimized treatment selection, improved survivorship, and better long-term outcomes for women worldwide.[60]

References

1. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov.* 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
2. Kumar RMH. Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models. *Int J Drug Deliv Technol.* 2026;16(65s):162-173.DOI:10.25258/ijddt.16.65s.19
3. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. *Nature.* 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881-4.

4. Rajendran LKK. Intelligent Omics-Driven Patient Stratification for Cancer Therapeutic Re-profiling. *International Journal of Clinical Research in Medical Sciences*. 2026;1(1):1-11. Doi:10.67231/gvshck05.
5. Rajendran LKK. Hematological Malignancy Identification via K-means based ROI Extraction. *International Journal of Clinical Research in Medical Sciences*. 2026;1(2):1-10. Doi:10.67231/kt1w3e73.
6. Maradi Hemanth Kumar R. Dynamic Digital Twins in Oncology: Foundation AI Models for Real-Time Predictive and Personalized Cancer Care. *Power System Protection and Control*. 2025;53(4):549-563. Doi:10.46121/pspc.53.4.38.
7. Kumar RMH. Pan-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models. *Power System Protection and Control*. 2023;51(4):92-100. Doi:10.46121/pspc.51.4.8.
8. Rajendran LKK. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery. *International Journal of Clinical Research in Medical Sciences*. 2026;1(2):1-10. Doi:10.67231/3acej759.
9. Maradi Hemanth Kumar R. AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology. *Power System Protection and Control*. 2023;51(4):66-83. Doi:10.46121/pspc.51.4.7.
10. Rajendran LKK. Machine Learning–Driven Symptom-Based Cancer Risk Stratification:A Systematic Review of Clinical Prediction Models and Methodological Rigor. *Int J Drug Deliv Technol*. 2026;16(40s):242-253.Doi:10.25258/ijddt.16.40s.26.
11. Kumar RMH. Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting. *Int J Drug Deliv Technol*. 2026;16(65s):174-185. DOI: 10.25258/ijddt.16.65s.20
12. Rajendran OK. Bias, Fairness, and Ethical Challenges in Artificial Intelligence: A Comprehensive Review of Causes, Impacts, and Mitigation Strategies. *Scientific Culture*. 2026;12(2.1):13001-13010. Doi:10.5281/zenodo.20374091.
13. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44–56. Doi:10.1038/s41591-018-0300-7.
14. Kumar RMH. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer. *Int J Drug Deliv Technol*. 2026;16(65s):186-200. DOI: 10.25258/ijddt.16.65s.21
15. Rajendran OK. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications. *Int J Drug Deliv Technol*. 2026;16(49s):956-964. Doi:10.25258/ijddt.16.49s.110.
16. Rajendran LKK. Interpretable Machine Learning for Early Mortality Prediction in Acute Myeloid Leukemia: A Decision Tree–Based Retrospective Cohort Study. *Int J Drug Deliv Technol*. 2026;16(40s):231-241.Doi:10.25258/ijddt.16.40s.25.
17. Kumar RMH. Self-Evolving Digital Twin Ecosystems for Early Detection and Precision Management of Breast, Lung, Colorectal, and Ovarian Cancers. *Int J Drug Deliv Technol*. 2026;16(65s):201-212. DOI: 10.25258/ijddt.16.65s.22
18. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. *Nat Med*. 2019;25(1):24–29. Doi:10.1038/s41591-018-0316-z.
19. Rajendran OK. Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis. *Int J Drug Deliv Technol*. 2026;16(49s):1010-1016. Doi:10.25258/ijddt.16.49s.117.
20. Rajendran LKK. Integrated Prognostic Modeling of Tumor Stage, Multimodal Therapy, and Functional Status in Lung Cancer Survival: A Real-World Cohort Study. *Scientific Culture*. 2026;12(5):567-576. Doi: 10.5281/zenodo.20738481.
21. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. *arXiv*. 2021. Doi:10.48550/arXiv.2108.07258.
22. Rajendran LKK. Integrative Pharmacogenomic Analysis of Drug Response Heterogeneity Across Cancer Cell Lines: Insights From Large-Scale GDSC Data. *Scientific Culture*. 2026;12(4):7537-7546. Doi:10.5281/zenodo.20767386.
23. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. *J Intern Med*. 2020;288(1):62–81. Doi:10.1111/joim.13030.
24. Rajendran OK. Tumor Microenvironment Interaction-Guided Graph Neural Networks for Survival Prediction from Whole-Slide Pathology Images. *Int J Drug Deliv Technol*. 2026;16(49s):481-488. Doi:10.25258/ijddt.16.49s.50.
25. Rajendran LKK. Evaluating the Association of Cancer-Related Risk Factors With Multisystem Health: Insights Into Fertility, Cardiovascular, and Renal Indicators. *Scientific Culture*. 2026;12(4):7520-7527.Doi:10.5281/zenodo.20767374.

26. Rajendran LKK. From Prediction to Precision: An Externally Validated Deep Learning–Based Survival and Adjuvant Therapy Recommendation System for Resected Stage III Non–Small Cell Lung Cancer. *Int J Drug Deliv Technol.* 2026;16(30s):430-438.doi:10.25258/ijddt.16.30s.41.
27. Kumar RMH. Multimodal foundation AI models in precision oncology: Integrating radiomics, pathomics, multi-omics, and clinical intelligence systems. *Power System Protection and Control.* 2024;52(4):189-204. Doi:10.46121/pspc.52.4.16.
28. Rajendran LKK. From Prediction to Practice: A Machine Learning–Based Clinical Decision Support Tool for Bevacizumab Risk Stratification in Oncology. *Int J Drug Deliv Technol.* 2026;16(30s):414-429. Doi:10.25258/ijddt.16.30s.40.
29. Rajendran OK. Self-supervised multimodal Learning for early cancer detection across Imaging and genomics. *Power System Protection and Control.* 2024;52(4):167-178. Doi:10.46121/pspc.52.4.14.
30. Rajendran OK. Explainable AI-Driven Clinical. Decision Support Systems in Precision Oncology:Interpretable Models for Multimodal Cancer Care. *Scientific Culture.* 2026;12(2.1):12359-12369. Doi:10.5281/zenodo.20328194.
31. Rajendran LKK. Impact of Treatment Modalities on Fertility, Sexual Function, and Psychological Outcomes in Testicular Cancer Survivors: A Comprehensive Review. *Int J Drug Deliv Technol.* 2026;16(30s):447-453. Doi:10.25258/ijddt.16.30s.43.
32. Rajendran LKK. Cancer nanomedicine: utilizing the enhanced permeability and retention (EPR) effect to deliver high payloads of chemotherapeutic agents directly to tumor sites. *Power System Protection and Control.* 2024;52(2):123-129. Doi:10.46121/pspc.52.2.12.
33. Kather JN, Calderaro J. Development of AI in digital pathology. *Nat Rev Clin Oncol.* 2020;17(10):591–595. Doi:10.1038/s41571-020-00431-0.
34. Rajendran OK. AI-based radiogenomic Models for predicting immunotherapy response In solid tumors. *Power System Protection and Control.* 2023;51(4):24-37. Doi:10.46121/pspc.51.4.4.
35. Rajendran LKK. Enhanced Predictive Analytics for Early Malignancy Discovery in Routine Screening. *International Journal of Clinical Research in Medical Sciences.* 2026;1(1):1-10. Doi:10.67231/grams870.
36. Rajendran OK. Machine Learning-Based Prediction of Chemotherapy Toxicity in Colorectal Cancer: A Personalized Risk Stratification Approach. *Scientific Culture.* 2026;12(5.1):942-952. Doi:10.5281/zenodo.20767359.
37. Rajendran OK. Federated radiology AI Models for multi-institutional cancer diagnosis Without data sharing. *Power System Protection And Control.* 2023;51(4):38-54. Doi:10.46121/pspc.51.4.5.
38. Kumar RMH. AI-augmented immuno-oncology: Foundation models for predicting immune response, resistance, and precision immunotherapy. *Power System Protection and Control.* 2024;52(2):193-208. Doi:10.46121/pspc.52.2.18.
39. Rajendran OK. Deep Reinforcement Learning in Oncology: Advances in Cancer Imaging, Radiotherapy, and Personalized Treatment. *Scientific Culture.* 2026;12(5):597-606. Doi:10.5281/zenodo.20767337.
40. Rajendran OK. DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING. *Power System Protection and Control.* 2025;53(3):313-328. Doi:10.46121/pspc.53.3.21.
41. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. *Nature.* 2021;594(7861):106–110. Doi:10.1038/s41586-021-03512-4.
42. Rajendran OK. Artificial Intelligence in Oncologic Imaging: Deep Learning, Radiomics, and Clinical Integration for Precision Cancer Diagnosis. *Int J Drug Deliv Technol.* 2026;16(50s):871-880. Doi:10.25258/ijddt.16.50s.92.
43. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the risk of colorectal cancer recurrence from histology images. *Lancet Oncol.* 2021;22(11):153–163. Doi:10.1016/S1470-2045(21)00430-5.
44. Rajendran OK. DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA. *Power System Protection and Control.* 2025;53(4):486-501. Doi:10.46121/pspc.53.4.33.
45. Rajendran LKK. Genomic profiling: utilizing Multi-omics data to identify potential Therapeutic targets and resistance markers. *Power System Protection and Control.* 2024;52(4):159-166. Doi:10.46121/pspc.52.4.13.
46. Rajendran OK. Artificial Intelligence–Driven Multimodal Imaging for Cancer During Pregnancy: Advances in Maternal–Fetal Diagnostics and Precision Oncology. *Int J Drug Deliv Technol.* 2026;16(50s):862-870. Doi:10.25258/ijddt.16.50s.91.
47. Rajendran LKK. Immunotherapy and cell Therapy: developing CAR-T cell therapies and Other immune-based treatments for cancer and Autoimmune diseases. *Power System Protection and Control.* 2023;51(2):64-77. Doi:10.46121/pspc.51.2.7.

48. Rajendran OK. FOUNDATION MODEL–DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE. *Power System Protection and Control*. 2024;52(2):154-163. Doi:10.46121/pspc.52.2.14.
49. Rajendran LKK. Theranostics: integrating Diagnostic imaging agents and therapeutic Drugs into a single multifunctional nano-Platform for real-time monitoring of treatment. *Power System Protection and Control*. 2025;53(2):376-386. Doi:10.46121/pspc.53.2.31.
50. Rajendran LKK. Mechanisms driving Immunotherapy resistance in colorectal cancer Liver metastases. *Power System Protection and Control*. 2024;52(1):29-37. Doi:10.46121/pspc.52.1.5.
51. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. *J R Soc Interface*. 2018;15(141):20170387. Doi:10.1098/rsif.2017.0387.
52. Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. *Med Image Anal*. 2017;42:60–88. Doi:10.1016/j.media.2017.07.005.
53. Hemanth Kumar RM. Integrated Transcriptomic and 3 Learning Framework Identifies a Blood-Based Biomarker Signature for Anthracycline-Induced Cardiotoxicity in Juvenile Cancer Survivors. *Int J Drug Deliv Technol*. 2026;16(40s):219-230. Doi:10.25258/ijddt.16.40s.24.
54. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. *Proc Natl Acad Sci USA*. 2018;115(13):E2970–E2979. Doi:10.1073/pnas.1717139115.
55. Rajendran OK. DeepDRA: A Deep Learning Framework for Drug Repurposing and Cancer Drug Response Prediction Using Multi-Omics Data. *Scientific Culture*. 2026;12(3):68-77. doi:10.5281/zenodo.20767428.
56. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol*. 2017;14(12):749–762. Doi:10.1038/nrclinonc.2017.141.
57. Azizi S, Mustafa B, Ryan F, et al. Big self-supervised models advance medical image classification. *Nature*. 2021;594(7864):104–110. Doi:10.1038/s41586-021-03476-6.
58. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. *arXiv*. 2020. Doi:10.48550/arXiv.2010.11929.
59. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. *Nature*. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
60. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. *Nature*. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.